AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2018
Oct 17, 2018
31523_dirs_2018-10-17_eb35caef-a077-4202-8d3f-ae2bfe21e5af.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2018-10-15
Reporting Person: Baird William D III (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-10-15 | Common Stock | M | 10000 | $2.45 | Acquired | 127622 | Direct |
| 2018-10-15 | Common Stock | S | 10000 | $12.2275 | Disposed | 117622 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-10-15 | Stock Options (right to buy) | $2.45 | M | 10000 | Disposed | 2024-01-03 | Common Stock (10000) | Direct |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.09 to $12.34. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: All of the options were fully vested and exercisable as of October 15, 2018.